Good morning, everyone, and welcome to another working week. Once again, a delightful weekend respite has come and gone, leaving us with the familiar challenge of tackling meetings, deadlines, and a growing to-do list. No doubt, you can relate, yes? So please join us as we cope with another cup of stimulation — as you know, a prescription is not required — and dig in for another busy day. Meanwhile, here are a few items of interest. Hope you have a smashing day and do stay in touch..
AstraZeneca (AZN) chief executive Pascal Soriot is grousing that he is not paid as much as his peers. “The truth is I’m the lowest-paid CEO in the whole industry,” he tells The Sunday Times. “It is annoying to some extent. But at the end of the day it is what it is.” Last year, his compensation totaled about $13.4 million, down from roughly $18.8 million the year before. “There’s other things in life than money. I’m not going to complain but me and Emma are the lowest paid in Europe and the U.S.,” he adds, referring to GlaxoSmithKline (GSK) Emma Walmsley.
As problems persist with its manufacturing plant in McPherson, Kan., Pfizer (PFE) plans to hire another 350 workers, The Wichita Eagle says. The drug maker attributes the move to “growing demand for Pfizer medicines, including growth in product lines at McPherson.” Pfizer experienced a series of debilitating issues that have caused numerous product shortages and prompted ongoing concerns from regulators at the plant, which makes about 75 percent of pre-filled syringes of opioid painkillers that are used in the U.S. for surgeries and treating pain.